| Committee Member | Employment | Consultant | Speakers Bureau | Ownership/Partnership/Principal | Personal Research | Institutional, Organizational, or Other Financial Benefit | Expert Witness |
|---|---|---|---|---|---|---|---|
| Donna K. Arnett, Co-Chair | University of Kentucky College of Public Health—Dean and Professor of Epidemiology | None | None | None | None | None | None |
| Roger S. Blumenthal, Co-Chair | Johns Hopkins University—Professor of Medicine and Director, Ciccarone Center for the Prevention of Heart Disease | None | None | None | None | None | None |
| Michelle A. Albert | UCSF School of Medicine—Professor of Medicine and Director, UCSF NURTURE Center | None | None | None | None | None | None |
| Andrew B. Buroker | Faegre Baker Daniels LLP, Partner | None | None | None | None | None | None |
| Zachary D. Goldberger | University of Wisconsin School of Medicine and Public Health—Associate Professor of Medicine, Division of Cardiology | None | None | None | None | None | None |
| Ellen J. Hahn | University of Kentucky College of Nursing—Professor & Director, BREATHE, Deputy Director, UK-CARES & Leader, and Community Engagement Core; Marcia A. Dake Professor of Nursing | None | None | None | None | None | None |
| Cheryl Dennison Himmelfarb | Johns Hopkins School of Nursing—Professor; Associate Dean Research, Office for Science and Innovation; and Deputy Director, Johns Hopkins Institute for Clinical and Translational Research | None | None | None | None | None | None |
| Amit Khera | UT Southwestern School of Medicine—Professor of Internal Medicine and Director, Preventive Cardiology Program | None | None | None | None | None | None |
| Donald Lloyd-Jones | Northwestern University—Eileen M. Foell Professor; Senior Associate Dean for Clinical and Translational Research; Chair, Department of Preventive Medicine; and Director, Clinical and Translational Sciences Institute | None | None | None | None | None | None |
| J. William McEvoy | National University of Ireland, Galway Campus—Professor of Preventive Cardiology; National Institute for Preventive Cardiology, Galway—Medical and Research Director; and University Hospital Galway, Ireland—Consultant Cardiologist. | None | None | None | None | None | None |
| Erin D. Michos | Johns Hopkins School of Medicine—Associate Professor of Medicine and Associate Director of Preventive Cardiology, Ciccarone Center for the Prevention of Heart Disease; Johns Hopkins Bloomberg School of Public Health—Associate Professor of Epidemiology | None | None | None | None | None | None |
| Michael D. Miedema | Minneapolis Heart Institute—Research Cardiologist | None | None | None | None | None | None |
| Daniel Muñoz | Vanderbilt University Medical Center—Assistant Professor of Medicine, Division of Cardiology, Medical Director for Quality, Vanderbilt Heart & Vascular Institute, and Associate Medical Director, Cardiovascular ICU | None | None | None | None | None | None |
| Sidney C. Smith Jr | University of North Carolina, Chapel Hill—Professor of Medicine, Division of Cardiology | None | None | None | None | None | None |
| Salim S. Virani | Baylor College of Medicine—Professor, Section of Cardiovascular Research and Director for Research, Cardiology Fellowship Training Program; Michael E. DeBakey VA Medical Center—Staff Cardiologist and Investigator, Health Policy, Quality & Informatics Program, Center for Innovations in Quality, Effectiveness and Safety | None | None | None | None | None | None |
| Kim A. Williams Sr | Rush Medical College—James B. Herrick Professor and Chief, Division of Cardiology, Department of Internal Medicine | None | None | None | None | None | None |
| Joseph Yeboah | Wake Forest Baptist Health—Associate Professor, Internal Medicine, Cardiovascular | None | None | None | None | None | None |
| Boback Ziaeian | University of California at Los Angeles/US Department of Veterans Affairs Greater Los Angeles Healthcare System, David Geffen School of Medicine—Assistant Professor, Division of Cardiology | None | None | None | None | None | None |
This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.
According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document or makes a competing drug or device addressed in the document; or c) the person or a member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.
ACC indicates American College of Cardiology; AHA, American Heart Association; ICU, Intensive Care Unit; LLP, Limited Liability Partnership; UCSF, University of California, San Francisco; UT, University of Texas; and VA, Veterans Affairs.